Aug. 28 at 1:25 PM
$SLS $MRK $MRNA Why was
$ABBV unable to enroll patients on Aza+VEN, the BAT for the SLS P3 Control ARM ?
• while we are seeing miraculous extended survival in the SLS p3?
$ABBV Claims they Could NOT ENROLL patients on Aza+VEN.
Gps has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance.
*Phase 3 Trial Results Imminent.
Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months.
$ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED.
GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months.
SOC: 24.7 --- GPs: > 67.6
Again Note the Key Gps Specific Immune Response.
Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant.
6.7% of the Onureg CR1 Patients Subsequently rec'd transplant.
I’ve been here a long time if your interested in Money scroll my posts
